Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | FHIT | P49789 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20320397 | 0.81 | CYP1A2 (0.43) | ALDH1A1CYP1A2MAPTNPC1RAB9A | |
| SCHEMBL23295662 | 0.80 | CYP1A2 (0.42) | ALDH1A1CYP1A2MAPTNPC1RAB9A | |
| SCHEMBL5391630 | 0.79 | NPSR1 (0.41) | ALDH1A1MAPTKMT2AMEN1HPGD | |
| SCHEMBL2594474 | 0.79 | KMT2A (0.42) | ALDH1A1CYP1A2MAPTNPC1RAB9A | |
| SCHEMBL352579 | 0.74 | CYP1A2 (0.54) | ALDH1A1CYP1A2MAPTNPC1RAB9A | |
| SCHEMBL10782782 | 0.73 | ALDH1A1 (0.35) | ALDH1A1CYP1A2MAPTNPC1RAB9A | |
| SCHEMBL10782787 | 0.73 | ALDH1A1 (0.35) | ALDH1A1CYP1A2MAPTNPC1RAB9A | |
| SCHEMBL7470982 | 0.73 | ALDH1A1 (0.35) | ALDH1A1CYP1A2MAPTNPC1RAB9A | |
| SCHEMBL10890650 | 0.72 | — | — | |
| SCHEMBL10839260 | 0.72 | SMN1; SMN2 (0.49) | ALDH1A1CYP1A2MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4696316-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260042740-A1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4054719-B1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12384750-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-11952352-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| US-20170240556-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | 4SC DISCOVERY GMBH (DE) | 2017-08-24 | — | — | US | disclosed |
| US-20170240556-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | 4SC DISCOVERY GMBH (DE) | 2017-08-24 | — | — | US | disclosed |
| US-5773624-A | Method for preparing 5-amino-1,2,4-thiadiazol acetic acid derivatives | KATAYAMA SEIYAKUSYO CO., LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
| EP-0795551-A1 | Method for preparing 5-amino-1,2,4-thiadiazol acetic acid derivatives | KATAYAMA SEIYAKUSYO CO. Ltd. (JP) | 1997-09-17 | — | — | EP | disclosed |
| WO-1993009101-A1 | MERCAPTO-AMIDE DERIVATIVES AS INHIBITORS OF THE NEUTRAL ENDOPEPTIDASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-13 | — | — | WO | disclosed |
| US-4837309-A | IMPROVED COLORFASTNESS AND LIGHTFASTNESS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1989-06-06 | — | — | US | disclosed |
| EP-0121825-B1 | MONOAZO DYESTUFFS FOR CELLULOSE-CONTAINING FIBERS | MITSUBISHI KASEI CORPORATION (JP) | 1986-09-10 | — | — | EP | disclosed |
| EP-0121825-A1 | Monoazo dyestuffs for cellulose-containing fibers | MITSUBISHI KASEI CORPORATION (JP) | 1984-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240556-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | CNKSR1, TYK2, ERBB2 | ALDH1A1 3599/4885CYP1A2 3098/4885MAPT 3006/4885 |
| US-20260042740-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 4551/4885CYP1A2 4723/4885MAPT 4692/4885 |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | ALDH1A1 4135/4885CYP1A2 4778/4885MAPT 3755/4885 |
| US-20230234929-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 4437/4885CYP1A2 4576/4885MAPT 3364/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | ALDH1A1 4528/4885CYP1A2 4879/4885MAPT 3227/4885 |
| US-20210130303-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 4437/4885CYP1A2 4576/4885MAPT 3364/4885 |
| US-12384750-B2 | Ras inhibitors | KRAS, NRAS, HRAS | ALDH1A1 4437/4885CYP1A2 4576/4885MAPT 3364/4885 |
| US-11952352-B2 | Ras inhibitors | KRAS, NRAS, HRAS | ALDH1A1 4437/4885CYP1A2 4576/4885MAPT 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.